Trial · NCT02781584
Results by group39
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 39
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 1: SEL 18 mg (Non-cirrhotic) | 50 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 2: FIR 20 mg (Non-cirrhotic) | 60 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 3: CILO 30 mg (Non-cirrhotic) | 50 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | 25 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | 40 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | 50 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 7: CILO 20 mg (Cirrhotic) | 80 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 8: CILO 30 mg (Cirrhotic) | 70 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | 76.92 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 10: FIR 20 mg + FENO 48 mg | 86.67 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 11: FIR 20 mg + FENO 145 mg | 87.5 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | 40 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg | 37.5 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events | Cohort 1: SEL 18 mg (Non-cirrhotic) | 0 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events | Cohort 2: FIR 20 mg (Non-cirrhotic) | 0 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events | Cohort 3: CILO 30 mg (Non-cirrhotic) | 0 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | 5 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | 5 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | 5 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events | Cohort 7: CILO 20 mg (Cirrhotic) | 10 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02781584/results